Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone858-203-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.19 million
Profitability
Miscellaneous
Employees382
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
How were Sorrento Therapeutics' earnings last quarter?
Sorrento Therapeutics Inc (NASDAQ:SRNE) announced its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The biopharmaceutical company earned $6.48 million during the quarter, compared to analysts' expectations of $7.50 million. Sorrento Therapeutics had a negative net margin of 1,107.37% and a negative return on equity of 119.51%. View Sorrento Therapeutics' Earnings History.
When is Sorrento Therapeutics' next earnings date?
What price target have analysts set for SRNE?
3 analysts have issued 12-month price targets for Sorrento Therapeutics' stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $17.3333 in the next year. This suggests a possible upside of 647.1% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.
What is the consensus analysts' recommendation for Sorrento Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.
What are Wall Street analysts saying about Sorrento Therapeutics stock?
Here are some recent quotes from research analysts about Sorrento Therapeutics stock:
- 1. According to Zacks Investment Research, "Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California. " (9/7/2019)
- 2. HC Wainwright analysts commented, "We ascribe a value of $5.5B based on a sum- of-the-parts approach, or a price per share of $30.00, assuming 183M projected fully-diluted shares outstanding as of mid-2020." (8/12/2019)
Has Sorrento Therapeutics been receiving favorable news coverage?
Media coverage about SRNE stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Sorrento Therapeutics.
Who are some of Sorrento Therapeutics' key competitors?
Some companies that are related to Sorrento Therapeutics include Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), HedgePath Pharmaceuticals (HPPI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX), US Stem Cell (USRM), Protalex (PRTX) and Geovax Labs (GOVX).
What other stocks do shareholders of Sorrento Therapeutics own?
Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the folowing people:
- Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
- Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
- Mr. George K. Ng, Corp. Sec. (Age 45)
- Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
- Ms. Deborah H. Telman, Sr. VP & Gen. Counsel
Who are Sorrento Therapeutics' major shareholders?
Sorrento Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.37%), Vanguard Group Inc. (3.92%), CVI Holdings LLC (1.07%), Northern Trust Corp (1.10%), Bank of New York Mellon Corp (0.37%) and Parametric Portfolio Associates LLC (0.25%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng and Pacific Medtech (Bvi) Ltd Asia. View Institutional Ownership Trends for Sorrento Therapeutics.
Which institutional investors are selling Sorrento Therapeutics stock?
Which institutional investors are buying Sorrento Therapeutics stock?
SRNE stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Vanguard Group Inc., BlackRock Inc., Charles Schwab Investment Management Inc., Price T Rowe Associates Inc. MD, Bank of America Corp DE, Centaurus Financial Inc. and Northern Trust Corp. View Insider Buying and Selling for Sorrento Therapeutics.
How do I buy shares of Sorrento Therapeutics?
Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sorrento Therapeutics' stock price today?
One share of SRNE stock can currently be purchased for approximately $2.32.
How big of a company is Sorrento Therapeutics?
Sorrento Therapeutics has a market capitalization of $303.87 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.
What is Sorrento Therapeutics' official website?
How can I contact Sorrento Therapeutics?
Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]
MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
